$11.32
-1.32-10.44%
At Close: -
$11.59
0.272.39%
After Hours: 6:57 PM EDT
15 minutes delayed
Comments
Loading...
Lexeo Therapeutics
LXEONASDAQ
want to know what
the Bulls & Bears Say?
Lexeo Therapeutics (NASDAQ:LXEO) Stock, Analyst Ratings, Price Targets, Forecasts
Lexeo Therapeutics Inc has a consensus price target of $22.29 based on the ratings of 7 analysts. The high is $28 issued by Baird on June 13, 2024. The low is $19 issued by Leerink Partners on November 28, 2023. The 3 most-recent analyst ratings were released by HC Wainwright & Co., Chardan Capital, and Baird on July 16, 2024, July 15, 2024, and June 13, 2024, respectively. With an average price target of $24.33 between HC Wainwright & Co., Chardan Capital, and Baird, there's an implied 109.95% upside for Lexeo Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Chardan Capital
Baird
RBC Capital
Leerink Partners
1calculated from analyst ratings
Analyst Ratings for Lexeo Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 07/16/2024 | Buy Now | 89.82% | HC Wainwright & Co. | Mitchell Kapoor | $22 → $22 | Reiterates | Buy → Buy | Get Alert |
| 07/15/2024 | Buy Now | 98.45% | Chardan Capital | Geulah Livshits | $23 → $23 | Maintains | Buy | Get Alert |
| 06/13/2024 | Buy Now | 141.59% | Baird | Brian Skorney | → $28 | Initiates | → Outperform | Get Alert |
| 06/06/2024 | Buy Now | 89.82% | HC Wainwright & Co. | Mitchell Kapoor | → $22 | Initiates | → Buy | Get Alert |
| 03/12/2024 | Buy Now | 107.08% | RBC Capital | Luca Issi | $22 → $24 | Maintains | Outperform | Get Alert |
| 11/28/2023 | Buy Now | 98.45% | Chardan Capital | Geulah Livshits | → $23 | Initiates | → Buy | Get Alert |
| 11/28/2023 | Buy Now | 63.93% | Leerink Partners | Mani Foroohar | → $19 | Initiates | → Outperform | Get Alert |
| 11/28/2023 | Buy Now | 89.82% | RBC Capital | Luca Issi | → $22 | Initiates | → Outperform | Get Alert |
| 11/28/2023 | Buy Now | 72.56% | Stifel | Paul Matteis | → $20 | Initiates | → Buy | Get Alert |
| 11/28/2023 | Buy Now | 72.56% | JP Morgan | Tessa Romero | → $20 | Initiates | → Overweight | Get Alert |
FAQ
What is the target price for Lexeo Therapeutics (LXEO) stock?
The latest price target for Lexeo Therapeutics (NASDAQ:LXEO) was reported by HC Wainwright & Co. on July 16, 2024. The analyst firm set a price target for $22.00 expecting LXEO to rise to within 12 months (a possible 89.82% upside). 10 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Lexeo Therapeutics (LXEO)?
The latest analyst rating for Lexeo Therapeutics (NASDAQ:LXEO) was provided by HC Wainwright & Co., and Lexeo Therapeutics reiterated their buy rating.
When was the last upgrade for Lexeo Therapeutics (LXEO)?
There is no last upgrade for Lexeo Therapeutics
When was the last downgrade for Lexeo Therapeutics (LXEO)?
There is no last downgrade for Lexeo Therapeutics.
When is the next analyst rating going to be posted or updated for Lexeo Therapeutics (LXEO)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Lexeo Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Lexeo Therapeutics was filed on July 16, 2024 so you should expect the next rating to be made available sometime around July 16, 2025.
Is the Analyst Rating Lexeo Therapeutics (LXEO) correct?
While ratings are subjective and will change, the latest Lexeo Therapeutics (LXEO) rating was a reiterated with a price target of $22.00 to $22.00. The current price Lexeo Therapeutics (LXEO) is trading at is $11.59, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.